Successful treatment of atopic dermatitis refractory to dupilumab with baricitinib
Dong Heon Lee
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorSo Yun Park
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorNarang Hong
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorHyung Don Kook
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorHye Jung Jung
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorMi Youn Park
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorCorresponding Author
Jiyoung Ahn
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Correspondence
Jiyoung Ahn, Department of Dermatology, National Medical Center, 245, Eulji-ro, Jung-gu, Seoul, Republic of Korea.
Email: [email protected]
Search for more papers by this authorDong Heon Lee
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorSo Yun Park
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorNarang Hong
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorHyung Don Kook
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorHye Jung Jung
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorMi Youn Park
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Search for more papers by this authorCorresponding Author
Jiyoung Ahn
Department of Dermatology, National Medical Center, Seoul, Republic of Korea
Correspondence
Jiyoung Ahn, Department of Dermatology, National Medical Center, 245, Eulji-ro, Jung-gu, Seoul, Republic of Korea.
Email: [email protected]
Search for more papers by this authorOpen Research
DATA AVAILABILITY STATEMENT
Data available on request from the authors. The data that support the findings of this study are available from the authors upon reasonable request.
REFERENCES
- 1Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015; 4: 858-873.
- 2Klonowska J, Gleń J, Nowicki RJ, et al. New cytokines in the pathogenesis of atopic dermatitis-new therapeutic targets. Int J Mol Sci. 2018; 19: 3086.
- 3Feldman SR, Cox LS, Strowd LC, et al. The challenge of managing atopic dermatitis in the United States. Am Health Drug Benefit. 2019; 12: 83-93.
- 4Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022; 21: 21-40.
- 5Jang DH, Heo SJ, Kook HD, et al. A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world. Sci Rep. 2021; 11: 23539.
- 6Halling AS, Loft N, Silverberg JI, et al. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol. 2021; 84: 139-147.
- 7Haddad EB, Cyr SL, Arima K, et al. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis. Dermatol Ther (Heidelb). 2022; 12: 1501-1533.
- 8Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of atopic dermatitis. Allergol Select. 2021; 5: 293-304.
- 9Kook HD, Hong N, Lee DH, et al. The effect of baricitinib add-on therapy in atopic dermatitis patients treated with dupilumab. Dermatol Ther. 2022; 35:e15525.
